New biologic shows promise for Tough-to-Treat ulcerative colitis

NCT ID NCT06626165

Completed Disease control Sponsor: Showa Inan General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether mirikizumab, a biologic drug, can improve symptoms and gut healing in 100 people with moderate-to-severe ulcerative colitis who had a specific type of inflammation seen on biopsy. Participants received either mirikizumab or vedolizumab, and doctors tracked changes in clinical activity and endoscopic scores. The goal is to see if mirikizumab offers a better option for patients not responding to standard maintenance therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mirikizumab (a biologic drug given by infusion or injection)
What this could lead to: If successful, this could confirm that mirikizumab helps control moderate-to-severe ulcerative colitis in patients with a specific type of gut inflammation.
What could go wrong: This is a small, completed Phase 4 study (100 people) without published results yet. It compares two existing drugs, so no breakthrough is expected, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

Showa Inan General Hospital

Komagane, Nagano, 399-4117, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.